HDAC9 and cancer: Histone deacetylase (HDAC) inhibitors have been approved for clinical treatment of various cancers including cutaneous T cell lymphoma [8], breast [9], non-Hodgkin's lymphoma and mantle cell lymphoma [10, 11].